IP Library Granted Patent US 10,716,498
Granted Patent B2
US 10,716,498 · App. 16/691,325 · Granted Jul 21, 2020

System and methods for processing analyte sensor data for sensor calibration

Inventors: Apurv Ullas Kamath (San Diego, CA); James H. Brauker (Addison, MI); Paul V. Goode, Jr. (Round Rock, TX); Aarthi Mahalingam (San Diego, CA); Jack Pryor (Ladera Ranch, CA)
Assignee: DexCom, Inc.
A61B5/14546A61B5/0031A61B5/1451A61B5/1473A61B5/1495A61B5/14532A61B5/14865A61B5/1468A61B5/1486A61B5/14503A61B5/14735A61B2560/0223Y02A90/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,716,498
App. No.
16/691,325
Granted
Jul 21, 2020
Kind
B2
Abstract

Systems and methods for processing sensor analyte data are disclosed, including initiating calibration, updating calibration, evaluating clinical acceptability of reference and sensor analyte data, and evaluating the quality of sensor calibration. The sensor can be calibrated using a calibration set of one or more matched sensor and reference analyte data pairs. Reference data resulting from benchtop testing an analyte sensor prior to its insertion can be used to provide initial calibration of the sensor data. Reference data from a short term continuous analyte sensor implanted in a user can be used to initially calibrate or update sensor data from a long term continuous analyte sensor.

Claims (15)

1. A method of making one or more glucose monitoring systems, the method comprising:

manufacturing one or more transcutaneous electrochemical glucose sensors, each transcutaneous electrochemical glucose sensor having an in vivo portion and an ex vivo portion;

examining an in vitro signal response of at least one of the one or more transcutaneous electrochemical glucose sensors for each of a plurality of known glucose concentrations;

calculating an in vitro sensitivity for at least one of the one or more transcutaneous electrochemical glucose sensors, based on the in vitro signal responses;

predicting an in vivo sensitivity for at least one of the one or more transcutaneous electrochemical glucose sensors based at least in part on (1) the calculated in vitro sensitivity and (2) a relationship between in vivo responses and in vitro data empirically established in at least one previously performed clinical study;

storing the predicted in vivo sensitivity in a memory; and

configuring one or more processors to calibrate data generated by at least one of the one or more transcutaneous electrochemical glucose sensors using the predicted in vivo sensitivity without reliance on any manual calibrations by a user of at least one of the one or more glucose monitoring systems following insertion of at least a portion of the at least one of the one or more transcutaneous electrochemical glucose sensors.

2. One or more glucose monitoring systems made by the method of claim 1 .

3. The method of making one or more glucose monitoring systems of claim 1 , further comprising manufacturing one or more sensor electronics, wherein each of the sensor electronics is configured to be placed in electrical communication with one of the one or more transcutaneous electrochemical glucose sensors.

4. The method of making one or more glucose monitoring systems of claim 3 , wherein each of the sensor electronics is configured to receive the data generated by the at least one of the one or more transcutaneous electrochemical glucose sensors.

5. A glucose monitoring system comprising:

a transcutaneous electrochemical glucose sensor having an in vivo portion and an ex vivo portion, wherein the in vivo portion is configured for insertion into a host; and

sensor electronics that are configured to provide calibrated glucose data based on sensor data provided by the transcutaneous electrochemical glucose sensor and a predicted in vivo sensitivity based at least in part on (1) a calculated in vitro sensitivity and (2) a relationship between in vivo responses and in vitro data empirically established in at least one previously performed clinical study associated with a plurality of transcutaneous electrochemical glucose sensors,

wherein the sensor electronics are in electrical communication with the transcutaneous electrochemical glucose sensor.

6. The glucose monitoring system of claim 5 , wherein the calibrated glucose data provided by the sensor electronics are not based on manual calibrations by a user of the glucose monitoring system following insertion of the in vivo portion of the transcutaneous electrochemical glucose sensor into a host.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2020
From: MAHALINGAM, AARTHI
To: DEXCOM, INC.
Reel/Frame 052808/0695 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 27, 2019
From: GOODE, PAUL V., JR.; BRAUKER, JAMES H.; KAMATH, APURV ULLAS
To: DEXCOM, INC.
Reel/Frame 051131/0769 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 27, 2019
From: PRYOR, JACK
To: DEXCOM, INC.
Reel/Frame 051132/0062 →
Continuity (8)
Continuation 16457628 · Jun 28, 2019
Continuation 15787595 · Oct 18, 2017
Continuation 15065623 · Mar 9, 2016
Continuation 13607162 · Sep 7, 2012
Continuation 12683755 · Jan 7, 2010
Continuation 11373628 · Mar 9, 2006
Provisional Application 60660743 · Mar 10, 2005
Related Publication 20200085356A1 · Mar 19, 2020
Cited By (4)
US 12,453,494 US 12,458,257 US 12,458,258 US 12,690,787